StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Zoledronic Acid

HCID 68740
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
118072-93-8
Standard-SMILES
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O
InChIKey
XRASPMIURGNCCH-UHFFFAOYSA-N
Summenformel
C5H10N2O7P2
Durchschnittliche Molmasse
272,09 g/mol
Monoisotopische Masse
271,99632466

Überblick

Zoledronic acid is an imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position. It has a role as a bone density conservation agent. It is a member of imidazoles and a 1,1-bis(phosphonic acid).

Namen und Bezeichner

Bevorzugter Name
Zoledronic Acid
IUPAC
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
Englischer Name
Zoledronic acid
Summenformel
C5H10N2O7P2
Molmasse
272.09

Namen und Synonyme

Zoledronic acid118072-93-8ZoledronateZometaReclastAclasta(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acidZoledronic Acid AnhydrousAnhydrous Zoledronic AcidCGP 42446Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-DTXSID0042668
Weitere Namen anzeigen
ZoledronicZolidronic AcidZoledronic Acid APIOrazolBPH 91
ZOL 44670HZ18PH24(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acidNSC-721517[1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acidPhosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-Zoledronic Acid ActavisDTXCID8022668

Datenbank-Bezeichner

CAS
118072-93-8
PubChem CID
68740
DTXSID
DTXSID0042668
ChEMBL
CHEMBL4303669、CHEMBL924
ChEBI
CHEBI:46557
UNII
70HZ18PH24
EC Number
871-741-2
Nikkaji
J556.181G

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-4,3
Polarare Oberfläche (TPSA)
153 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
4
Schwere Atome
16
Formalladung
0
Komplexität
327

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-4.2
Solubility · 2 Einträge

Sparingly soluble

3.27e+00 g/L

Human Drugs · 6 Einträge

Breast Feeding; Lactation; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt
193 · 193-2040C (dec)
Siedepunkt
764 · 764.0±70.0 °C(Predicted)
Dichte
2.13 · 2.13±0.1 g/cm3(Predicted)
storage temp.
Sealed in dry,Room Temperature
Löslichkeit
Soluble in Water (up to 2 mg/ml).
Aggregatzustand
solid
pka
1.41 · 1.41±0.10(Predicted)
Farbe
White or off-white
Stabilität
2 years · Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 2 months.
InChI
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
InChIKey
XRASPMIURGNCCH-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(O)CN1C=NC=C1
CAS Datenbank
118072 · 118072-93-8(CAS DataBase Reference)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P261, P264+P265, P272, P280, P302+P352, P305+P351+P338, P321, P333+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesSkin Sens. 1 (100%)

Toxikologische Informationen

Adverse Effects · 1 Eintrag

The commonly reported adverse reactions include pyrexia, headache, myalgia, pain in extremities, and arthralgia. Significant adverse effects associated with zoledronate include hypocalcemia, secondary hyperparathyroidism, acute phase response (APR), renal injury, atypical femur fractures, osteonecrosis of the jaw (ONJ), atrial fibrillation, and ocular inflammation.

Exposure RoutesIntravenous. Poorly absorbed (oral absorption is about 1% of what intravenous absorption is).
Toxicity Summary · 2 Einträge

In the event of toxicity or overdose, no reversal agents are approved by the FDA for this drug. In a case report, a pediatric patient with osteogenesis imperfecta experienced a substantial 15-fold overdose of zoledronate. The patient received 4 mg (0.37 mg/kg) instead of the intended 0.27 mg (0.025 mg/kg) dosage, resulting in severe hypocalcemia and hypophosphatemia, necessitating calcium and phosphorus supplementation with ergocalciferol administration. Despite supportive care and hemodialysis initiation to address electrolyte imbalances and potentially eliminate excess zoledronate, the patient experienced multiple episodes of nonsustained ventricular tachycardia. This case underscores the need for prolonged monitoring and electrolyte supplementation in pediatric Zoledronate overdose cases to address potential complications, including severe hypocalcemia and hypophosphatemia.

The action of zoledronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Zoledronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates such as zoledronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Signs and Symptoms · 1 Eintrag

There is no experience of acute overdose. Two patients received zoledronate (32 mg) over 5 minutes in clinical trials. Neither patient experienced any clinical or laboratory toxicity. Overdosage may cause clinically significant hypocalcemia, hypophosphatemia, and hypomagnesemia.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Zoledronic acid

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

hs_code
2933399090
risk_code
21/22-36/37/38
hazard_code
Xi
safety_code
24/25-36/37/39

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

M05BA08

M - Musculo-skeletal system

QM - Musculo-skeletal system

M05BA08

Protein BindingZoledronic acid is 23-53% protein bound in plasma.
Pharmacodynamics · 1 Eintrag

Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption. The therapeutic window is wide as patients are unlikely to suffer severe effects from overdoses and the duration of action is long. Patients should be counselled regarding the risk of electrolyte deficiencies, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, bronchoconstriction, hepatic impairment, hypocalcemia, and embryo-fetal toxicity.

Mechanism of Action · 1 Eintrag

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Etidronic acid also inhibits V-ATPases in the osteoclast, though the exact subunits are unknown, preventing F-actin from forming podosomes. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as zoledronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. zoledronate also activated caspases which further contribute to apoptosis.

Biological Half-LifeZoledronic acid has a terminal elimination half life of 146 hours.
Metabolism/Metabolites · 2 Einträge

Zoledronic acid is not metabolized _in vivio_.

Zoledronate does not inhibit human P450 enzymes in vitro and does not undergo biotransformation in vivo. Route of Elimination: In 64 patients with cancer and bone metastases, on average (± s.d.) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post-Day 2. Half Life: 146 hours

FDA Pharmacological Classification · 6 Einträge

70HZ18PH24

ZOLEDRONIC ACID ANHYDROUS

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Zoledronic acid anhydrous is a Bisphosphonate.

ZOLEDRONIC ACID

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 3 Einträge

A 4mg intravenous dose reaches a Cmax of 370±78.5ng/mL, with a Tmax of 0.317±0.014h, and an AUC of 788±181ng\*h/mL. A 5mg intravenous dose reaches a Cmax of 471±76.1ng/mL, with a Tmax of 0.368±0.005h, and an AUC of 917±226ng\*h/mL.

Zoledronic acid is 39 ± 16% eliminated in the urine as the unmetabolized parent drug.

Zoledronic acid has a renal clearance of 3.7 ± 2.0 L/h.

Cellular LocationsCytoplasm
Metabolite PathwaysZoledronate Action Pathway

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg) in USA (2002): 1

For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget's Disease.

Anwendungen · 2 Einträge

BeschreibungZoledronic acid is a white, crystalline powder that is available in vials for reconstitution for IV infusion over at least 15 minutes. It does not undergo metabolic transformation and does not inhibit CYP450 enzymes. Clearance of this agent is dependent on the patient's creatinine clearance, not on dose. Serum creatinine levels should be evaluated before every treatment. Zolendronic acid is contraindicated in patients with severe renal impairment.

VerwendenZoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Phosphorige Säure-trichloridOrthophosphorsure2-(1H-Imidazol-1-yl)acetyl chlorideImidazol-1-yl-acetic acidEthyl 1H-imidazole-1-acetateWasser

Ergänzende Hinweise

DefinitionChEBI: An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.

Zugehörige Reaktionen

115
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 730591
HRID 730591als Edukt
Reaktionsgleichung von HRID 730592
HRID 730592als Edukt
Reaktionsgleichung von HRID 730593
HRID 730593als Edukt
Reaktionsgleichung von HRID 730594
HRID 730594als Edukt
Reaktionsgleichung von HRID 730595
HRID 730595als Edukt
Reaktionsgleichung von HRID 730596
HRID 730596als Edukt
Reaktionsgleichung von HRID 730597
HRID 730597als Edukt
Reaktionsgleichung von HRID 730598
HRID 730598als Edukt
ZurückSeite 1 von 15

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung